Business
Immuron’s commercially available products found to neutralise COVID-19 during in vitro research – Small Caps
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.
IMM-124E is used in Immurons over-the-counter Travelan and Protectyn products which were developed as immunotherapeutics to prevent travellers diarrhea and other gastrointestinal and digestive issues.
The products are commercially available, with Travelan currently registered for use across Australia, Cana…
-
General21 hours agoZac Lomax released by Eels for ‘opportunities outside NRL’, fuelling speculation of R360 switch
-
General19 hours agoIslam Makhachev claims UFC welterweight belt with dominant win over Jack Della Maddalena
-
Noosa News9 hours agoGovernment auditors suspected lab was conducting shonky tests on infrastructure projects
-
Noosa News22 hours agoState government renews national demand for health funding